VCT220 + itraconazole

VCT220 + itraconazole is an experimental combination in which **VCT220** (also designated as CX11) and **itraconazole** are co-administered. VCT220 is an investigational, once-daily oral **small molecule glucagon-like peptide-1 receptor agonist (GLP-1 RA)** being developed for **obesity and overweight**. In phase 2 trials, VCT220 demonstrated about 5.8%–9.7% weight loss at 16 weeks with favorable tolerability and no liver toxicity. Itraconazole is an **azole antifungal** that inhibits fungal ergosterol synthesis and is a potent **CYP3A4 inhibitor**. Itraconazole also inhibits drug transporters such as P-glycoprotein and BCRP. In drug interaction studies, the combination is used to investigate potential effects of CYP3A4-mediated pharmacokinetic interactions due to VCT220 being a CYP3A4 substrate.

Other names

CX11 + itraconazole